Shares of Koninklijke Philips (NYSE:PHG – Get Free Report) have been assigned an average rating of “Hold” from the five research firms that are covering the company, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company.
Several equities research analysts have weighed in on PHG shares. StockNews.com downgraded Koninklijke Philips from a “buy” rating to a “hold” rating in a report on Thursday, November 14th. Jefferies Financial Group raised shares of Koninklijke Philips from an “underperform” rating to a “hold” rating in a research report on Tuesday, October 29th.
Check Out Our Latest Stock Report on Koninklijke Philips
Institutional Trading of Koninklijke Philips
Koninklijke Philips Stock Performance
Shares of PHG stock opened at $25.81 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.74 and a debt-to-equity ratio of 0.60. The company has a market cap of $24.26 billion, a PE ratio of -61.45, a PEG ratio of 0.92 and a beta of 0.77. Koninklijke Philips has a 12-month low of $19.55 and a 12-month high of $32.91. The business’s fifty day simple moving average is $26.00 and its 200-day simple moving average is $28.07.
Koninklijke Philips Company Profile
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.
Recommended Stories
- Five stocks we like better than Koninklijke Philips
- Earnings Per Share Calculator: How to Calculate EPS
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- What is Forex and How Does it Work?
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Koninklijke Philips Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Koninklijke Philips and related companies with MarketBeat.com's FREE daily email newsletter.